Editorspicks
Numinus Receives Approvals to Start Recruiting Participants in MAPS PBC Study
Numinus Wellness Inc. (TSX:NUMI) (OTC:NUMIF) is a Canadian company that helps heal people’s mental health through psychedelic-assisted therapies. The Numinus model is at the forefront of a transformation aimed at healing rather than managing the more...
Editorspicks
Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product
Finalized study design and protocol mark major milestone to investigate natural Psilocybin VANCOUVER, BC, Oct. 20, 2021 /CNW/ – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF) (“Numinus” or the “Company”), a leader in psychedelics-focused mental healthcare, is pleased more...
Editorspicks
Numinus to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th
VANCOUVER, BC, Oct. 6, 2021 /PRNewswire/ — Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF)(“Numinus” or the “Company”), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the KCSA more...
Editorspicks
Numinus Completes Acquisition of Neurology Centre of Toronto
Acquisition strengthens clinic portfolio for mental health treatment using psychedelic-assisted therapies VANCOUVER, BC, Sept. 23, 2021 /CNW/ – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF)(“Numinus” or the “Company”), a mental health care company advancing innovative treatments and safe, evidence-based more...
Editorspicks
Numinus to Participate in Upcoming Investor Conferences in September 2021
VANCOUVER, BC, Sept. 2, 2021 /CNW/ – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF)(“Numinus” or the “Company”), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in two upcoming more...
Editorspicks
Numinus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into Psychedelic Neurology
VANCOUVER, BC, July 29, 2021 /CNW/ – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF)(“Numinus” or the “Company”), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its fiscal third-quarter results ended May 31, more...
Editorspicks
Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSD
Real-world study expands access to MDMA-assisted therapy for patients with PTSD and concurrent disorders and will provide data on a regulated model for MDMA-assisted therapy VANCOUVER, BC, July 12, 2021 /CNW/ – Numinus Wellness Inc. more...
Editorspicks
Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create Centre for Psychedelic Neurology
NCT’s treatment of neurological disorders combined with Numinus’ leadership in psychedelic-assisted therapy will offer opportunity to treat a range of chronic neurological conditions and common concurrent mental health challenges VANCOUVER, BC, July 6, 2021 /PRNewswire/ – more...
Editorspicks
Numinus Wellness Graduates to Tier 1 on the TSX Venture Exchange
VANCOUVER, BC, June 18, 2021 /PRNewswire/ – Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF)(“Numinus” or the “Company”), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it has received approval more...
Editorspicks
Numinus Announces Update to Escrow Release Schedule
VANCOUVER, BC, June 25, 2021 /PRNewswire/ –Numinus Wellness Inc. (TSXV:NUMI)(OTCPK:LKYSF)(“Numinus” or the “Company”), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that, in relation to its graduation more...
